Siemens Healthineers Capital Markets Day Summary Company Overview - **Company**: Siemens Healthineers (OTCPK: SEMH.F) - **Event**: 2025 Capital Markets Day - **Date**: November 17, 2025 Key Points Industry Position and Strategy - Siemens Healthineers is recognized as a leader in the healthcare industry, particularly in imaging and precision therapies, with a strong presence in the Americas, Europe, China, and APJ regions [6][9][10] - The company operates in 70 countries and has an installed base of 700,000 systems, impacting 3 billion patients annually [6][7] - The focus is on elevating health globally, addressing non-communicable diseases (NCDs) which account for 75% of global deaths [17][18] Financial Performance - Revenue growth has averaged over 6% per year since the last capital market day, with EPS growth at 11% per year [10][58] - Siemens Healthineers reported revenues of over EUR 23 billion and EBIT close to EUR 4 billion [9] - The company has a backlog of over EUR 6 billion from value partnerships [8][12] Research and Development - Siemens Healthineers invests more than EUR 2 billion annually in R&D, with a focus on software, AI, and data science [7] - The company holds 1,300 patent families in healthcare AI, showcasing its commitment to innovation [7] Business Segments - The company operates in three synergistic business segments: Imaging, Varian (Precision Therapy), and Advanced Therapies, with Diagnostics following a separate path [9][13] - Diagnostics has improved margins by 8 percentage points since 2023 and is expected to have more entrepreneurial freedom for strategic growth [13] Future Growth and Targets - Midterm growth targets (2027-2030) include revenue growth of 5-9% and double-digit EPS growth [41][42] - The company aims for margin expansion of about 100 basis points per year in Precision Therapy and mid-single-digit growth in Diagnostics [42] - Sustainability targets include reducing carbon footprint by 90% in scope one and two by 2030 [42] Customer Challenges - Key challenges for customers include efficiency, clinical excellence, and access to care, driven by staff shortages and the need for improved healthcare systems [34][35][36] - Siemens Healthineers aims to address these challenges through value partnerships and innovative solutions [37][38] Technological Innovations - The company is focusing on personalized treatment approaches for NCDs, leveraging AI and advanced imaging technologies [22][23][24] - Innovations such as photon counting CT and AI-enabled MRI are positioned to enhance early detection and treatment planning [25][29] Capital Allocation and Financial Strategy - Siemens Healthineers has a stable dividend policy, proposing EUR 1.00 per share for the next AGM, with a commitment to maintain a progressive dividend [52] - The company targets a net debt to EBITDA ratio of 2.5 over the next two years, aiming for a strong investment-grade rating [54] Conclusion - Siemens Healthineers is well-positioned to tackle significant healthcare challenges through its innovative technologies, strong market presence, and strategic focus on growth and sustainability [39][40]